Syndax Pharmaceuticals Inc.

126 articles with Syndax Pharmaceuticals Inc.

• Syndax to Present at the JMP Securities Life Sciences Conference

  6/13/2019

  Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that Michael A. Metzger, President and Chief Operating Officer of Syndax, will present at the JMP Securities Life Sciences Conference on Thursday, June 20, 2019 at 10:00 a.m. ET at the St. Regis New York.

• Syndax to Present at the UBS Global Healthcare Conference

  5/14/2019

  Syndax Pharmaceuticals, Inc. announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the UBS Global Healthcare Conference on Tuesday, May 21, 2019 at 10:30 a.m. ET at the Grand Hyatt New York.

• Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update

  5/6/2019

  E2112 trial passes fourth interim analysis for OS; trial to continue, with next preplanned analysis expected in 4Q19

• Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019

  4/29/2019

  Syndax Pharmaceuticals, Inc. announced that it will release its first quarter 2019 financial results on Monday, May 6, after the close of the U.S. financial markets.

• Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting

  4/1/2019

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the presentation of updated findings from the melanoma and non-small cell lung cancer (NSCLC) cohorts of ENCORE 601,

• Syndax Announces $26.2 Million Offering of Common Stock and Warrants

  3/27/2019

  Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it has entered into an agreement with Biotechnology Value Fund, L.P.

• Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update

  3/7/2019

  Next interim OS assessment for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q19

• Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019

  2/28/2019

  Syndax Pharmaceuticals, Inc. announced that it will release its fourth quarter 2018 financial results on Thursday, March 7, after the close of the U.S. financial markets.

• Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019

  2/27/2019

  Syndax Pharmaceuticals, Inc. announced two oral presentations at the upcoming American Association for Cancer Research Annual Meeting being held March 29 - April 3, 2019 in Atlanta, Georgia.

• Syndax Highlights 2019 Clinical and Corporate Outlook

  1/7/2019

  Data from ENCORE I/O combination program in melanoma and ovarian cancer expected in 1Q19, TNBC in 2Q19

• Syndax Pharmaceuticals Announces Presentation of Preclinical Data from Menin-MLL Program at the 60th American Society of Hematology Annual Meeting

  12/3/2018

  Preclinical data provide further support for the clinical application of Company's Menin-MLL program in acute leukemias

• Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update

  11/5/2018

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter ended September 30, 2018.

• Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting 

  11/1/2018

  Syndax Pharmaceuticals, Inc. today announced that the Company’s Menin-MLLr program will be featured during two presentations at the 60th American Society of Hematology (ASH) Annual Meeting being held December 1-4, 2018 in San Diego, California. 

• Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting

  11/1/2018

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company's Menin-MLLr program will be featured during two presentations at the 60th American Society of Hematology (ASH) Annual Meeting

• Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018

  10/29/2018

  Syndax Pharmaceuticals, Inc. announced today that it will release its third quarter 2018 financial results on Monday, November 5, after the close of the U.S. financial markets.

• Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer

  10/25/2018

  Enrollment completed in E2112; PFS not statistically significant; trial continues as planned having passed 3rd interim analysis for OS with additional planned OS analyses every 6 months

• Syndax to Present at the 2018 Cantor Global Healthcare Conference

  9/26/2018

  2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 9:10 a.m. ET at the InterContinental New York Barclay Hotel.

• 

  28-7 Therapeutics Raises $65 Million to Advance Tumor Suppressor Research

  9/7/2018

  Twentyeight-Seven Therapeutics (28-7), announced it had completed a $65 million Series A financing. It was co-led by founding investor MPM Capital and Novartis Venture Fund. Joining them were Johnson & Johnson Innovation – JJDC, Vertex Ventures, Longwood Fund, and Astellas Venture Management.

• Syndax Announces Participation at Three Upcoming September 2018 Investor Conferences

  8/28/2018

  Syndax Pharmaceuticals, Inc. today announced that members of the management team will participate in three upcoming investor conferences.

• Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update

  8/7/2018

  Syndax Pharmaceuticals Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2018. In addition, the Company provided a clinical and business update. As of June 30, 2018, Syndax had $98.4 million in cash, cash equivalents and short-term investments.